REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc., carrying the ticker TZAC, filed an 8-K current report with the SEC on December 23, 2025, disclosing a material corporate development. The company emerged from a SPAC combination with TZP Strategies Acquisition Corp, a blank-check vehicle sponsored by TZP Group that completed its initial public offering in 2021 with a focus on the healthcare and biopharmaceutical sector. Reviva Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for central nervous system and cardiometabolic conditions. The December filing represents a post-combination disclosure under the combined entity's reporting obligations. Sign up at SpacDesk for full filing history, sponsor profiles, and deal analytics on TZAC and thousands of other SPAC transactions.